Literature DB >> 21527129

Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.

Carolyn I Rodriguez, Lawrence S Kegeles, Pamela Flood, Helen Blair Simpson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21527129      PMCID： PMC3727240          DOI： 10.4088/JCP.10l06653

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  17 in total

1.  N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.

Authors:  Daniel L Lafleur; Christopher Pittenger; Ben Kelmendi; Tom Gardner; Suzanne Wasylink; Robert T Malison; Gerard Sanacora; John H Krystal; Vladimir Coric
Journal:  Psychopharmacology (Berl)       Date:  2005-12-22       Impact factor: 4.530

Review 2.  Mechanism of action of memantine.

Authors:  Jon W Johnson; Shawn E Kotermanski
Journal:  Curr Opin Pharmacol       Date:  2005-12-20       Impact factor: 5.547

3.  Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS).

Authors:  J D Bremner; J H Krystal; F W Putnam; S M Southwick; C Marmar; D S Charney; C M Mazure
Journal:  J Trauma Stress       Date:  1998-01

4.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

5.  Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

Authors:  Vladimir Coric; Sarper Taskiran; Christopher Pittenger; Suzanne Wasylink; Daniel H Mathalon; Gerald Valentine; John Saksa; Yu-Te Wu; Ralitza Gueorguieva; Gerard Sanacora; Robert T Malison; John H Krystal
Journal:  Biol Psychiatry       Date:  2005-09-01       Impact factor: 13.382

6.  Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice.

Authors:  Jeffrey M Welch; Jing Lu; Ramona M Rodriguiz; Nicholas C Trotta; Joao Peca; Jin-Dong Ding; Catia Feliciano; Meng Chen; J Paige Adams; Jianhong Luo; Serena M Dudek; Richard J Weinberg; Nicole Calakos; William C Wetsel; Guoping Feng
Journal:  Nature       Date:  2007-08-23       Impact factor: 49.962

7.  Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

Authors:  Elias Aboujaoude; John J Barry; Nona Gamel
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

8.  Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients.

Authors:  B D Greenberg; J Benjamin; J D Martin; D Keuler; S J Huang; M Altemus; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1998-12       Impact factor: 4.530

9.  Acute changes in obsessions and compulsions following moderate-intensity aerobic exercise among patients with obsessive-compulsive disorder.

Authors:  Ana M Abrantes; David R Strong; Amy Cohn; Amy Y Cameron; Benjamin D Greenberg; Maria C Mancebo; Richard A Brown
Journal:  J Anxiety Disord       Date:  2009-06-24

10.  Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.

Authors:  Jamie D Feusner; Lauren Kerwin; Sanjaya Saxena; Alexander Bystritsky
Journal:  Psychopharmacol Bull       Date:  2009
View more
  17 in total

Review 1.  Pharmacological treatment of anxiety disorders: current treatments and future directions.

Authors:  Frank J Farach; Larry D Pruitt; Janie J Jun; Alissa B Jerud; Lori A Zoellner; Peter P Roy-Byrne
Journal:  J Anxiety Disord       Date:  2012-08-15

2.  In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept.

Authors:  Carolyn I Rodriguez; Lawrence S Kegeles; Amanda Levinson; R Todd Ogden; Xiangling Mao; Matthew S Milak; Donna Vermes; Shan Xie; Liane Hunter; Pamela Flood; Holly Moore; Dikoma C Shungu; Helen B Simpson
Journal:  Psychiatry Res       Date:  2015-06-06       Impact factor: 3.222

Review 3.  Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors:  Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal:  Pharmacol Ther       Date:  2011-09-22       Impact factor: 12.310

4.  Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept.

Authors:  Carolyn I Rodriguez; Jordana Zwerling; Eyal Kalanthroff; Hanyang Shen; Maria Filippou; Booil Jo; Helen Blair Simpson; Ronald M Burch; Joseph R Moskal
Journal:  Am J Psychiatry       Date:  2016-12-01       Impact factor: 18.112

5.  Effects of ketamine in treatment-refractory obsessive-compulsive disorder.

Authors:  Michael H Bloch; Suzanne Wasylink; Angeli Landeros-Weisenberger; Kaitlyn E Panza; Eileen Billingslea; James F Leckman; John H Krystal; Zubin Bhagwagar; Gerard Sanacora; Christopher Pittenger
Journal:  Biol Psychiatry       Date:  2012-07-10       Impact factor: 13.382

Review 6.  Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity.

Authors:  Dennis L Murphy; Pablo R Moya; Meredith A Fox; Liza M Rubenstein; Jens R Wendland; Kiara R Timpano
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

7.  Glutamatergic agents for OCD and related disorders.

Authors:  Christopher Pittenger
Journal:  Curr Treat Options Psychiatry       Date:  2015-09

8.  Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.

Authors:  Carolyn I Rodriguez; Michael Wheaton; Jordana Zwerling; Shari A Steinman; Danae Sonnenfeld; Hanga Galfalvy; Helen Blair Simpson
Journal:  J Clin Psychiatry       Date:  2016-03       Impact factor: 4.384

9.  Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Authors:  Carolyn I Rodriguez; Lawrence S Kegeles; Amanda Levinson; Tianshu Feng; Sue M Marcus; Donna Vermes; Pamela Flood; Helen B Simpson
Journal:  Neuropsychopharmacology       Date:  2013-06-19       Impact factor: 7.853

10.  Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.

Authors:  Reilly R Kayser; Margaret Haney; Marissa Raskin; Caroline Arout; Helen Blair Simpson
Journal:  Depress Anxiety       Date:  2020-05-07       Impact factor: 6.505
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.